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The cetylpyridinium chloride (CPC) has been used as micellar catalyst in three-component one-pot reaction involving 
thiobarbituric acids, aromatic aldehydes and β-napthol for synthesizing the novel 2-thioxo-benzo[5,6]chromeno[2,3-
d]pyrimidin-4-one derivatives in aqueous media. These 2-thioxo-benzo[5,6]chromeno[2,3-d]pyrimidin-4-one derivatives
have been screened for antioxidant and cytotoxic activities. It has been found that 2-thioxo-5-(4-nitrophenyl)-
benzo[f]chromeno[2,3-d]pyrimidin-4-one (4a) has shown highest scavenging activity value to reduce DPPH free radicals,
which may be due to the presence of nitro group at para-position. Three compounds, 4a, 4b and 4o show significant in vitro
antitumor activity. The study of the antioxidant and cytotoxic activities reveal that all the compounds show moderate to
good activity indicating that the presence of thiouriedo linkage in the pyrimidine nucleus and the chromeno group attached
to pyrimidene moiety are responsible for these activities.
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Development of newer methods for the synthesis of 
biologically active compounds and catalysis in 
water medium is an intense area of research
1-4
. One 
of the drawbacks of water as solvent is the low 
solubility of most organic substrate in this medium. 
This can be overcome by using organic solvent as 
co-solvent or surfactants which can solubilize 
organic solvents under miceller condition
5-7
. The role 
of surfactants in organic reactions may be explained 
that it is possible to make the insoluble and less 
soluble compounds soluble in aqueous water by 
penetrating through the hydrophobic core of 
micelles. It is suggested that the reagent having 
either polar or non-polar counterparts can be 
incorporated in micelles making it easier to 
solubilize. The solubilising capacity can also be 
increased by using co-solvents and even with 
variable temperature conditions. In micellar solution, 
the organic substrates solvated in the interior 
lipophilicity (hydrophobicity) of micelles created by 
the surfactants, and thereby facilitates a smooth 
reaction
8
. Increased reaction rates are usually 
observed when organic reactions are performed in 
aqueous solutions in presence of surfactants
9
. 






 and are used as antagonists for 
Neuropeptide S receptor (Figure 1)
17
. Recently, 
racemic benzochromenopyrimidinones are reported as 
non-hepatotoxic, acetylcholinesterase inhibitors with 
anti-oxidative properties (Figure 2)
18
. 
Although the benzochromenopyrimidinones are 
biologically important compounds, very few 
literatures are reported for the synthesis of these 
compounds. It was reported that the sulfonic acid-
functionalized nanoparticles could be used as 
catalysts for the synthesis of 5-aryl-1H-benzo 
[f]chromeno[2,3-d]pyrimidine-2,4(3H,5H)-dione
derivatives in terms of activity and recyclability
19
.
Syntheses of naphthopyranopyrimidine derivatives by
three component cyclocondensation of β-naphthol,
aldehydes, and cyclic 1,3-dicarbonyl compounds










 and InCl3 or P2O5
24 
were recently
reported. One-pot, three-component synthesis of
naphthopyranopyrimidines was also reported from
β-naphthol, aldehydes, and 6-amino-1,3-dimethyluracil














under solvent-free conditions. However, these methods 
used for the synthesis of benzochromenopyrimidine 
derivatives were accomplished with expensive 
catalysts, complex, strong acids, long reaction time 
and of moderate yields. Moreover, the synthesis of  
2-thioxo-5-aryl-benzo[f]chromeno[2,3-d]pyrimidin-4-
one derivatives is not known to the best of our 
knowledge as reported syntheses were only for benzo-
chromenopyrimidines and benzochromenopyrimidinones. 
In continuation of our work on the development of 
newer methods for the synthesis of heterocyclic 
compounds
29-32
 and fused heterocyclic compounds
33-35
, 
herein we are reporting the surfactant miceller 
catalyzed synthesis of novel 2-thioxo-
benzochromenopyrimidine-4-ones by one-pot three-
component reaction of thiobarbituric acids, aldehydes 
and β-napthol in aqueous media. The methodology 
adopted for the synthesis of 2-thioxo-
benzochromenopyrimidine-4-ones offers several 
advantages such as use of environmentally benign 
non-toxic catalyst, efficient, short reaction time, 
simple experimental and purification procedure, and 
excellent yields. Furthermore, the anti-oxidant 
properties and the cytotoxicity of the synthesized 
compounds were determined. It was found that the 
pyrimidine nucleus containing thiouriedo linkage (-
NH-C(S)-NH-) is pharmaceutically important because 
the development of medicine mainly arose from the 
heterocyclic compounds containing nitrogen and 
sulphur atoms. Thus, for the first time the catalytic 
effect of surfactant in the synthesis of 2-thioxo-
benzochromenopyrimidine-4-ones is described. 
 
Results and Discussion 
 
Chemistry 
Initial attempt for optimisation towards the 
synthesis of 2-thioxo-benzochromenopyrimidinone 
derivatives (4) was carried out using one pot multi-
component reaction of 2-thiobarbituric acid (1a),  
p-nitrobenzaldehyde (2a) and β-napthol (3) under 
micellar condition (Scheme I). 
First, the reaction was stirred at room temperature 
and in refluxing condition in water without any 
catalyst to establish the real efficiency of catalysis, it 
was found that no desired product was obtained 
(Table I, entries 1 and 2). The model reaction was 
again carried out at room temperature using 
water:acetonitrile (1:1) as solvent, even in this 
condition, no desired product was formed (Table I, 
entry 3). The reaction was then optimized with 
different surfactants as catalyst, so as to help in 
reducing the reaction time and improved yield of the 
target product. The less expensive and easily available 
anionic and cationic surfactants, such as, sodium 
 
 




Figure 2 — Cholinesterase inhibitors 
 




dodecyl sulphate (SDS), cetyl trimethyl ammonium 
bromide (CTAB), cetyl pyridinium chloride (CPC), 
tetradecyl trimethyl ammonium bromide (TTAB), 
tetra ethyl ammonium bromide (TEAB), etc. were 
employed as catalysts (15 mol%) for this reaction. 
After screening several catalysts in water, it can be 
noted that the reaction gave the product in low yields 
(Table I, entries 4-9). The improvement of the yield 
can be seen when water with medium polarity solvent 
acetonitrile is used in 1:1 volume. The reason for this 
may be attributed to the enhance solubility of 
substrates by acetonitrile. 
 
 
Scheme I — Synthesis of 2-thioxo-5-aryl-2,3-dihydro-1H-benzo[6,7]chromeno[2,3-d]pyrimidin-4(5H)-one 4 
 






















Entry Surfactant (mol%) Solvent Temperature (°C) Time (h) Yield of 4a (%) 
1 No catalyst H2O RT
a 48 NPb 
2 No catalyst H2O reflux 48 NP
b 
3 No catalyst CH3CN: H2O reflux 48 NP
b 
4 SDS (15) H2O RT
a 48 <10 
5 SDS (15) H2O reflux 48 32 
6 TTAB (15) H2O reflux 48 40 
7 CTAB (15) H2O reflux 48 35 
8 CPC (15) H2O reflux 48 53 
9 TEAB (15) H2O reflux 48 45 
10 SDS (15) CH3CN: H2O RT
a 48 46 
11 SDS (15) CH3CN: H2O 80
oC 48 52 
12 SDS (15) CH3CN: H2O reflux 24 65 
13 TTAB (15) CH3CN: H2O reflux 12 80 
14 CTAB (15) CH3CN: H2O reflux 12 85 
15 CPC (15) CH3CN: H2O reflux 8 94 
16 TEAB (15) CH3CN: H2O reflux 12 85 
17 CPC (20) CH3CN: H2O reflux 12 88 
18 CPC (10) CH3CN: H2O reflux 12 82 
a Room temperature (RT) was 40oC; b No desired product (NP) 
 




To acquire the best effect of reaction, a number of 
surfactants in water: acetonitrile solvent was tried by 
refluxing (Table I). The longer time of reaction with 
lesser yields were found when surfactants, like SDS, 
TTAB, CTAB, TEAB (Table I, entries 12, 13, 14, 16) 
were used. It may be noted that the anionic surfactant 
SDS either at ambient temperature or under refluxing 
condition gave the desired product in low yields, 
46%, 52% and 65%, respectively (Table I, entries 10, 
11 and 12). It was observed that among the cationic 
surfactants, CPC was found to be the efficient catalyst 
to yield the desired product in high 94% yield 
(Table I, entry 15). The effect of amount of the 
catalyst loading was also evaluated in model reaction 
by refluxing in water:acetonitrile solvent. It was 
shown that 15 mol% of the catalyst was the best 
choice for the completion of reaction. When the 
amount of the catalyst was increased to 20 mol%, it 
was found that there was no effect on the yield as well 
as on the duration of the reaction (Table I, entry 17). 
Again, on reducing the amount of the catalyst  
(10 mol%), it gave lesser yield of the desired product 
(Table I, entry 18).  
To expand the scope and versatility of the reaction 
under the optimized condition, reactions were 
performed using various aryl aldehydes to give the 
products in good to excellent yields (Table II). It may 
be noted that the reaction when carried out with  
bulky groups has no effect on the steric hinderance  
of the product (4c, 4d). In addition, when N,N-
dimethylbenzaldehyde and 2,5-dimethoxybenzaldehyde, 
that is, in presence of strong electron donating  
groups, the reactions were tolerated and gave  
the yields in 85% and 80%, respectively (Table II, 
entries 5 and 8). Interestingly, when aliphatic 
aldehydes,  such  as,  butyaldehyde  was  used, the  




















Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 











8 85 207-210 










10 80 198-203 
     (Contd.) 
 

























Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 










4 93 188-191 










3 85 195-197 









4 85 205-208 









4 92 201-204 
     (Contd.) 
 

























Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 









5 75 188-191 










4 80 185-187 










4 95 205-209 









4 90 200-203 
     (Contd.) 

























Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 
11 1k, 












9 90 215-217 
12 1l, 

























12 90 257-259 
14 1n, 














11 92  
     (Contd.) 

























Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 
15 1o, 














9 90  
16 1p, 














8 89 250-252 
17 1q, 














6 90  
     (Contd.) 
 

























Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 
18 1r, 














7 91  
19 1s, 
















5 86  
20 1t, 














7 88  
21 1u, 












8 92 309-312 
     (Contd.) 




desired product was formed but in lesser yield 
(Table II, entry 7, 4g). 
A plausible mechanism for the synthesis of 2-
thioxo-5-aryl-2,3-dihydro-1H-benzo[6,7]chromeno 
[2,3-d]pyrimidin-4(5H)-one (4) from 2-thiobarbituric 
acid (1), aldehyde (3) and β-napthol (2) under 
micellar condition is shown in Scheme II. 
 
Antioxidant activity 
Antioxidants, free radical scavengers, are thought 
to have a role in the prevention of cellular damage - 
the common pathway for cancer, aging, and a variety 
of diseases. Many heterocyclic compounds containing 
free radical scavengers are gaining importance for the 
treatment of such diseases. The primary anti-oxidative 
activity can be evaluated by using 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical. The free radical 
scavenging activity of the compound was evaluated 
for hydrogen ion donating or free radical scavenging 
ability using the stable free radical DPPH method of 
Lee et al.
36
 with some modifications. The methanolic 
solution of DPPH was rapidly mixed with the 
methanolic sample and the absorbance at 515 nm was 
measured after 5 mins. BHT (Butylated hydroxy 
toluene) solution was used as a reference 
corresponding to 100% radical scavenging activity. 
It was found that 2-thioxo-5-aryl-2,3-dihydro-1H-
benzo[6,7]chromeno[2,3-d]pyrimidin-4(5H)-ones (4a-
4o) reduced DPPH free radicals in a concentration 
dependent manner. The scavenging activities of these 
compounds are shown in Table III. The results 
showed that compound 4a (78.3%) having highest 
scavenging activity value followed by 4b (66.4%), 4l 
(64.1%), and 4o (62.5%) are more active; and 4d 
(54.1%), 4f (43.3%), 4i (42.2) are as active as the 
positive control, 4c (30.8%), 4k (24.7%), 4e (16.1%), 
4m (8.4%), 4n (7.7%), 4g (4.9%), 4h (2.1%) and 4j 
(1.6%) showed very less activity. The mechanism  
of reaction between antioxidants and DPPH is 
dependent upon the structural conformation of the 
antioxidants which could be attributed to their 
hydrogen donating ability. 
 
Cytotoxicity 
The anti-tumour activities of the target compounds 
against human hepatoma cell line (HepG2) were 
determined using cytotoxicity assay and were 
assessed in comparison to Taxol on the basis of 
monitoring the inhibition of the growth of human 
cancer cells by using MTT assay
37,38
. MTT assay is a 
rapid and high accuracy colorimetric approach that 
widely used to determine cell growth and cell 
cytotoxicity, particularly in the development of new 
drug. It measures cell membrane integrity by 
determining mitochondrial activity through enzymatic 
reaction on the reduction of MTT to formazan. 
Synthesized compounds (4a-4o) were subjected to a 
screening system for investigation of their antitumor 
potency against liver (HepG2) cell line. The 
concentrations that induce 50% inhibition of cell 
growth (IC50) in mM are reported in Table IV. The 
antitumor activity results indicated that most of  the  




















Entry 1 3 4 Time (h) Yield (%) m.p. (°C) 
22 1v, 













9 91 250-252 
 







Scheme II — Plausible mechanism for the synthesis of 2-thioxo-5-aryl-2,3-dihydro-1H-benzo[6,7]chromeno[2,3-d]pyrimidin-4(5H)-one 4 




Table III — DPPH free radical scavenging activity of different 
concentrations of 4 
Sl. No. Compd Radical scavenging activitya (%) 
1 4a 78.3 
2 4b 66.4 
3 4c 30.8 
4 4d 54.1 
5 4e 16.1 
6 4f 43.3 
7 4g 4.9 
8 4h 2.1 
9 4i 42.2 
10 4j 1.6 
11 4k 24.7 
12 4l 64.1 
13 4m 8.4 
14 4n 7.7 
15 4o 62.5 
a All analyses were performed in triplicate and the data were 
recorded as mean 
 
Table IV — In vitro antitumor activity of the synthesized 
compounds 
Compd Viability % IC50  
(µg/mL)a 
Sample concentration (µg m-1) 
50 25 12.5 6.25 3.12 1.56 
4a 22.40 67.74 86.99 97.83 100.0 100.0 17.4 
4b 27.81 84.66 93.29 99.12 100.0 100.0 23.6 
4c 28.72 46.99 73.91 89.63 98.12 100.0 34.8 
4d 26.60 71.09 91.41 98.18 100.0 100.0 36.5 
4e 19.87 69.49 84.74 91.09 98.46 100.0 34.8 
4f 27.81 84.66 93.29 99.12 100.0 100.0 40.2 
4g 15.83 62.88 79.62 87.44 96.92 100.0 31.8 
4h 28.33 72.31 81.54 95.86 100.0 100.0 37.7 
4i 26.60 71.09 91.41 98.18 100.0 100.0 36.9 
4j 45.77 71.28 86.92 97.24 100.0 100.0 45.9 
4k 28.82 77.60 91.30 98.11 100.0 100.0 38.3 
4l 31.85 76.16 89.79 96.84 100.0 100.0 29.8 
4m 26.43 73.86 87.43 96.07 100.0 100.0 37.6 
4n 18.38 68.45 77.82 90.53 98.51 100.0 35.7 
4o 27.43 79.04 92.27 98.05 100.00 100.0 24.2 
Taxolb 10.95 14.29 16.90 21.03 30.32 100.0 1.2 
aIC50, compound concentration required to inhibit tumor cell 
proliferation by 50%. 
bPositive control. Experiments were performed in triplicate. 
 
compounds showed inhibition activity against the 
tested cell line but varying intensity extents in 
comparison to the known anticancer drug (Taxol). 
Compounds 4a, 4b and 4o showed significant in vitro 
antitumor activity (IC50, 17.4 µg/mL, 23.6 µg/mL, and 
24.2 µg/mL), and thus, the presence of thiouredo 
moiety and fusion of chromeno-ring in pyrano-
pyrimido structures enhance the antitumor activity. 
Experimental Section 
The melting points were determined on a Buchi  
M-560 melting point apparatus and are uncorrected. 
Infrared (IR) spectra were recorded on Shimadzu  





. All the samples were run on a sodium 
chloride plate as a liquid film. Absorption maxima 
were recorded in wave numbers (cm
-1
). Proton nuclear 
magnetic resonance (
1
H NMR) spectra were recorded 
on BRUCKER–ACF-300 (300 MHz). Carbon nuclear 
magnetic resonance (
13
C NMR) spectra were recorded 
on BRUCKER-ACF-300 (75 MHz). All chemical 
shifts are reported in parts per million (δ) relative to 
tetramethylsilane (TMS), reference to the chemical 





NMR). Coupling constants are given in Hz. All 
samples are run in deutero-chloroform (CDCl3)  
and DMSO. The FAB mass spectra were recorded  
at 6000 Mass Spectrometed data systems using 
Argon/Xenon (6KV, 10mA) as the FAB gas. The 
accelerating voltage was 10 KV and the spectra were 
recorded at room temperature. All the commercial 
chemicals were distilled before use. 
 
General procedure for the synthesis of 2-thioxo-
bezochromenopyrimidin-4-ones, 4a-j 
In a typical experiment, p-nitrobenzaldehyde 3a 
(1.0 mmol), β-napthol 2 (0.144g, 1.0 mmol), 
thiobarbituric acid 1a (1.0 mmol) and CPC (0.015 
mmol %) were taken in a round bottom flask using 
water (2.5 mL) and acetonitrile (2.5 mL) as solvent in 
1:1 ratio. The reaction mixture was refluxed and the 
progress of the reaction was monitored by TLC. After 
completion of reaction (8 h), the solid obtained was 
collected by filtration and washed successively with 
water (3 × 10 mL) and with acetonitrile (3 × 5 mL). 
The crude product was recrystallized from ethanol to 
afford the pure compound 4a which required no 
further purification. 
2-Thioxo-5-(4-nitrophenyl)-benzo[f]chromeno 
[2,3-d]pyrimidin-4-one, 4a: Yellow solid; m.p. 207-
210°C; IR (KBr): νmax 3541, 1651, 1537, 1445, 1350, 




H NMR (DMSO-d6,  
300 MHz): ∂ 5.70 (s, 1H), 6.72 (m, 1H), 6.85 (m, 1H), 
7.01 (d, 2H, J=7.6 Hz), 7.24 (m, 4H), 7.67 (d, 2H, 
J=7.6 Hz), 10.90 (br s, 1H), 11.20 (br s, 1H);
 13
C 
NMR (DMSO-d6, 75 MHz): ∂ 173.6, 152.9, 145.7, 
128.3, 123.5, 95.6, 31.6; Anal. Calcd. for 
C21H13N3O4S: C 65.12, H 3.38, N 10.85; Found: C 
64.83, H 3.64, N 10.54. 





[2,3-d]pyrimidin-4-one, 4b: White solid; m.p: 198-
203°C; IR (KBr): νmax 3524, 1660, 1537, 1443, 1359, 




H NMR (DMSO-d6,  
300 MHz): ∂ 5.80 (s, 1H), 6.97-7.22 (m, 10H), 11.32 
(br s, 1H), 11.69 (br s, 1H);
 13
C NMR (DMSO-d6, 75 
MHz): ∂173.4, 164.0, 163.0, 142.7, 129.8, 128.9, 
128.0, 96.0, 30.6; HRMS (EI) cald. 393.0464; found 
393.0478. Anal. Calcd. for C21H13ClN2O2S: C 65.12, 
H 3.38, N 10.85; Found: C 64.83, H 3.64, N 10.54. 
2-Thioxo-5-(1H-indol-3-yl)-benzo[f]chromeno 
[2,3-d]pyrimidin-4-one, 4c: White solid; m.p: 188-





H NMR (DMSO-d6, 300 MHz): ∂ 
5.80 (s, 1H), 6.97-7.22 (m, 10H), 12.28 (br s, 1H), 
12.32 (br s, 1H), 13.01 (br s, 1H);
 13
C NMR (DMSO-
d6, 75 MHz): ∂ 178.2, 163.3, 161.5, 145.1, 141.5, 
137.1,129.5, 124.5, 123.6, 118.4, 113.9, 112.9, 109.2, 
29.5; HRMS (EI) cald for C21H13ClN2O2S: 304.3127; 
found 304.3238. 
2-Thioxo-5-(3-hydroxynaphthalen-1-yl)-benzo[f] 
chromeno[2,3-d]pyrimidin-4-one, 4d: White solid; 
m.p: 195-198
0
C; IR (KBr): νmax 3452, 3032, 1678, 





d6, 300 MHz): ∂ 5.56 (s, 1H), 7.15 (m, 2H), 7.22 (m, 
2H), 7.55 (m, 2H), 7.60 (m, 2H), 7.88 (m, 2H), 8.22 
(m, 2H), 11.55 (br s, 1H), 12.20 (br s, 1H);
 13
C NMR 
(DMSO-d6, 75 MHz): ∂ 174.9, 173.5, 160.3, 156. 8, 
148.3, 131.4, 129.8, 128.0, 126.6, 126.5, 123.1, 119.1, 
109.1, 43.2, 29.6; HRMS (EI) cald for C25H18N2O3S: 
426.1038; found 426.4870. 
2-Thioxo-5-(4-N,N-dimethylanilino)-benzo[f] 
chromeno[2,3-d]pyrimidin-4-one, 4e: White solid; 
m.p: 205-208
0
C; IR (KBr): νmax 3457, 3119, 1634, 





(DMSO-d6, 300 MHz): ∂ 3.00 (s, 3H), 3.02 (s, 3H), 
5.90 (s, 1H), 6.75 (m, 2H), 7.22 (m, 2H), 7.40 (m, 
2H), 8.22 (m, 2H), 8.48 (m, 2H), 11.98 (br s, 1H), 
12.05 (br s, 1H);
 13
C NMR (DMSO-d6, 75 MHz): ∂ 
178.0, 173.5, 163.5, 161.0, 156.7, 155.3, 140.3, 128.6, 
120.9, 112.0, 109.8, 95.9, 46.1, 30.9; HRMS (EI) cald 
for C23H19N3O2S: 401.1198; found 401.4809. 
2-Thioxo-5-(4-carbaldehydophenyl)-benzo[f] 
chromeno[2,3-d]pyrimidin-4-one, 4f: White solid; 
m.p: 201-203
0
C; IR (KBr): νmax 3522, 3148, 1670, 





(DMSO-d6, 300 MHz): ∂ 4.50 (s, 1H), 5.90 (s, 1H), 
7.12-8.25 (m, 10H), 11.62 (br s, 1H), 12.25 (br s, 1H), 
12.42 (br s, 1H);
 13
C NMR (DMSO-d6, 75 MHz): ∂ 
178.4, 173.5, 162.5, 145.2, 132.7, 128.6, 61.3, 29.6; 
HRMS (EI) cald for C22H14N2O3S: 386.4232; found 
386.0725. 
2-Thioxo-5-propyl-benzo[f]chromeno[2,3-d] 
pyrimidin-4-one, 4g: White solid; m.p: 188-192
0
C; 





H NMR (DMSO-d6, 300 MHz): ∂ 0.82 (m, 3H), 
1.18 (m, 2H), 2.28 (m, 2H), 5.78 (m, 1H), 7.12 (m, 
2H), 7.32-7.45 (m, 2H), 7.65-7.72 (m, 2H), 11.98 (br 
s, 1H), 12.05 (br s, 1H);
 13
C NMR (DMSO-d6, 75 
MHz): ∂ 178.2, 157.3, 145.5, 135.3, 129.8, 128.6, 
128.0, 126.6, 126.5, 123.1, 119.1, 109.1, 31.8, 29.6, 
22.4, 14.5; HRMS (EI) cald for C18H16N3O2S: 
324.0932; found 324.3968. 
2-Thioxo-5-(2,4-dimethoxyphenyl)-benzo[f] 
chromeno[2,3-d]pyrimidin-4-one, 4h: White solid; 
m.p: 185-187
0
C; IR (KBr): νmax 3181, 1688, 1576, 





NMR (DMSO-d6, 300 MHz): ∂ 3.73 (s, 3H), 3.85  
(s, 3H), 4.56 (s, 1H), 7.08-7.23 (m, 5H), 7.40-8.13  
(m, 4H), 12.34 (br s, 1H), 12.48 (br s, 1H);
 13
C NMR 
(DMSO-d6, 75 MHz): ∂ 178.5, 161.7, 159.4, 155.2, 
154.1, 150.1, 145.4, 129.2, 128.0, 126.1, 125.9, 122.6, 
121.6, 121.2, 118.4, 117.0, 56.3, 55.5, 28.8; HRMS 
(EI) cald for C23H20N2O4S: 420.4809; found 420.1144. 
2-Thioxo-5-(3-nitrophenyl)-benzo[f]chromeno 
[2,3-d]pyrimidin-4-one, 4i: White solid; m.p: 185-
187
0
C; IR (KBr): νmax 3181, 1688, 1576, 1543,  




H NMR (DMSO-d6, 300 MHz): ∂ 5.75 (s, 1H),  
7.38-7.43 (m, 4H), 7.65 (d, J = 8.4 Hz, 1H), 7.88-8.07 
(m, 4H), 8.17 (d, J = 9.2 Hz, 1H), 12.14 (br s, 1H), 
12.38 (br s, 1H);
 13
C NMR (DMSO-d6, 75 MHz):  
∂ 173.1, 163.8, 153.6, 148.7, 138.4, 133.8, 131.3, 
125.6, 123.1, 116.9, 89.4, 33.8; Anal. Calcd. for 
C21H13N3O4S: C 65.12, H 3.38, N 10.85; Found: C 
65.04, H 3.63, N 10.26. 
2-Thioxo-5-(4-methoxyphenyl)-benzo[f]chromeno 
[2,3-d]pyrimidin-4-one, 4j: White solid; m.p: 185-
187
0
C; IR (KBr): νmax 3181, 1688, 1576, 1543, 1495, 





d6, 300 MHz): ∂ 3.63 (s, 3H), 5.56 (s, 1H), 6.82 (d, J 
= 8.2 Hz, 2H), 7.11-7.26 (m, 4H), 7.32-7.88 (m, 4H), 
11.34 (br s, 1H), 12.18 (br s, 1H);
 13
C NMR (DMSO-
d6, 75 MHz): ∂ 177.8, 164.3, 158.2, 153.8, 150.4, 
146.7, 132.2, 131.0, 129.8, 129.2, 127.6, 125.8, 124.2, 
118.7, 114.5, 89.6, 56.3, 55.6, 33.8; Anal. Calcd. for 
C22H16N2O3S: C 65.12, H 3.38, N 10.85; Found: C 
65.04, H 3.63, N 10.26. 





[2,3-d]pyrimidin-4-one, 4k: White solid; m.p: 215-
217
0





H NMR (DMSO-d6, 300 MHz): ∂ 0.82 
(m, 3H), 1.18 (m, 2H), 2.28 (m, 2H), 5.78 (m, 1H), 
7.12 (m, 2H), 7.32-7.45 (m, 2H), 7.65-7.72 (m, 2H), 
11.98 (br s, 1H), 12.05 (br s, 1H);
 13
C NMR (DMSO-
d6, 75 MHz): ∂ 178.2, 157.3, 145.5, 135.3, 129.8, 
128.6, 128.0, 126.6, 126.5, 123.1, 119.1, 109.1, 31.8, 
29.6, 22.4, 14.5; HRMS (EI) cald for C18H16N3O2S: 
324.0932; found 324.3968. 
 
Antioxidant activity 
Aliquots (50 mL) of the extract dilution at a 
concentration range of 0.1– 2 mg/mL were mixed 
with 450 mL Tris–HCl buffer (pH = 7.4) and 1 mL of 
the methanolic DPPH solution (0.1 mM). The 
mixtures were left for 30 min at room temperature in 
the dark and the absorbance at 517 nm was measured 
using MeOH as blank. Extract concentration 
providing 50% inhibition (IC50) was calculated using 
the graph by plotting inhibition percentage against 
extract concentration. Synthetic antioxidant reagent 
butylated hyroxytoluene (BHT) was used as a positive 
control. The measurements were performed in 
triplicate and the results were averaged. Radical 
scavenging activity was expressed as percentage 
inhibition of DPPH radical and was calculated by the 
following equation:  
DPPH Scavenged (%) = [(Acont - Atest)/ Acont] × 100 
where, Acont is the absorbance of the control reaction 
and Atest is the absorbance in the presence of the 




Cell Line Culture 
Human ovarian carcinoma cell line, A2780 was 
obtained from the European Collection of  
Cell Culture (ECACC). Cells were cultured in  
RPMI 1640 media supplemented with 10%  
foetal bovine serum, glutamine (2mM) and 1 % 
penicillin-streptomycin in static 75 cm
2
 TFlask 
(GIBCO, USA). The cells were incubated in a 




Cell Cytotoxicity Assay 
Cells were plated in a 96-well-plate with 1 X  
105 cells/well of concentration. The cells were  
left to adhere for 48 hours before exposed to  
the plant extracts (0-1000 μg/ml) administered  
in media containing 1% of FBS and returned  
to the incubator for 48 hrs. Subsequently, 3-(4,5-
dimethylthaizol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) reagent (0.5 mg/mL in sterile 
Phosphate buffer salin, PBS) was added directly  
to the wells. Cells were returned to the incubator  
for 4 hrs. The formation of insoluble purple  
formazan from yellowish MTT by enzymatic 
reduction was dissolved in DMSO after removal of 
supernatant. The optical density of solution was 
measured at 590 nm using a microplate reader 
(ELx808, BioTek, USA). 
 
Cell Viability Assay 
After treatment with the synthesized compounds, 
the cells were pooled together and the remaining 
attached cells were detached from the culture plates 
by exposure to trypsin-EDTA. The resultant cells 
were then stained with trypan blue at the 
concentration of 0.2%. Then, the trypan blue-
excluded viable cells were counted using a 




In conclusion, an efficient, simple way of 
synthesizing the substituted 2-thioxo-benzochromeno 
[2,3-d]pyrimidin-4-one derivatives in good to 
excellent yields was developed. Here, for the first 
time, the use of CPC as a catalyst for the synthesis of 
a series of novel 2-thioxo-bezochromenopyrimidin-4-
one derivatives as one pot multi component reaction 
has been described without using any harmful and 
toxic organic solvents. It was found that the 
compounds having electron withdrawing group  
in the ring (4a, 4b, 4l and 4o) showed high 
antioxidant activities. The cytotoxic activity results 
indicated that most of the tested compounds (4a, 4b 
and 4o) showed anti-tumour activity against the tested 
cell line. Thus the study of the antioxidant and 
cytotoxic activities revealed that all the tested 
compounds showed moderate to good activities 
indicating that the presence of thiouriedo linkage in 
the pyrimidine nucleus and the chromeno group 




Supplementary information is available in the website 
http://nopr.niscair.res.in/handle/123456789/60. 
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